rupatadine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
histamine-H1 receptor antagonists, tricyclic compounds 2413 158876-82-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • rupatadine fumarate
  • rupatadine
  • alergoliber
  • pafinur
  • rinialer
  • rupafin
  • rupax
Rupatadine is a second-generation antihistamine, long-acting histamine antagonist with selective peripheral H1-receptor and platelet activating factor (PAF) antagonistic activities. Some of the metabolites (desloratadine and its hydroxylated metabolites) retain an antihistaminic activity and may partially contribute to the overall efficacy of the drug, maintaining activity for up to 24 hours.
  • Molecular weight: 415.97
  • Formula: C26H26ClN3
  • CLOGP: 5.06
  • LIPINSKI: 1
  • HAC: 3
  • HDO: 0
  • TPSA: 29.02
  • ALOGS: -4.88
  • ROTB: 2

Drug dosage:

DoseUnitRoute
10 mg O

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Sept. 27, 2017 PMDA Teikoku Seiyaku

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urticaria 166.02 28.69 81 1555 117811 46566615
Skin plaque 95.55 28.69 25 1611 5810 46678616
Asthma 67.12 28.69 41 1595 91501 46592925
Lipohypertrophy 49.18 28.69 10 1626 762 46683664
Vascular access site infection 44.82 28.69 6 1630 30 46684396
Vascular access site thrombosis 44.65 28.69 6 1630 31 46684395
Pruritus 42.37 28.69 47 1589 242305 46442121
Cutaneous T-cell lymphoma 38.22 28.69 9 1627 1354 46683072
Osteoporotic fracture 35.67 28.69 10 1626 2995 46681431
Expiratory reserve volume decreased 34.41 28.69 5 1631 49 46684377
Mediastinal haematoma 31.69 28.69 5 1631 88 46684338
Sneezing 31.32 28.69 13 1623 12728 46671698
Sinonasal obstruction 30.50 28.69 5 1631 113 46684313

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urticaria 67.71 50.70 30 644 54576 29897228
Nasal oedema 54.52 50.70 9 665 338 29951466

Pharmacologic Action:

SourceCodeDescription
ATC R06AX28 RESPIRATORY SYSTEM
ANTIHISTAMINES FOR SYSTEMIC USE
ANTIHISTAMINES FOR SYSTEMIC USE
Other antihistamines for systemic use

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Allergic rhinitis indication 61582004
Urticaria indication 126485001

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.22 Basic
pKa2 3.82 Basic
pKa3 3.17 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Histamine H1 receptor GPCR ANTAGONIST IC50 8.41 CHEMBL KEGG DRUG
Platelet-activating factor receptor GPCR IC50 5.43 CHEMBL

External reference:

IDSource
D07407 KEGG_DRUG
182349-12-8 SECONDARY_CAS_RN
C0534301 UMLSCUI
CHEBI:135673 CHEBI
CHEMBL91397 ChEMBL_ID
133017 PUBCHEM_CID
10103 IUPHAR_LIGAND_ID
C103639 MESH_SUPPLEMENTAL_RECORD_UI
7443 INN_ID
DB11614 DRUGBANK_ID
2AE8M83G3E UNII
013131 NDDF
013132 NDDF

Pharmaceutical products:

None